W. Feely

发表

Nivolumab plus ipilimumab in advanced melanoma.

C. Horak, J. Wolchok, M. Sznol, 2013, The New England journal of medicine.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

J. Wolchok, M. Atkins, J. Kirkwood, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Photodegradation of avermectin B1a thin films on glass

W. Feely, B. Arison, L. Colwell, 1991 .

Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function

W. Feely, R. Preston, Samir K. Gupta, 2012, Clinical Pharmacokinetics.

1085OSURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIAL OF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL).

J. Wolchok, M. Atkins, J. Kirkwood, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Normal Phase High Performance Liquid Chromatography of Some Prostaglandin B1 Derivatives

W. Feely, R. Dorman, H. W. Shmukler, 1989 .

Improving tall fescue (Festuca arundinacea) for cool-season vigour

W. Feely, S. L. Clement, K. Reed, 2004 .

Determination and confirmation of 5-hydroxyflunixin in raw bovine milk using liquid chromatography tandem mass spectrometry.

W. Feely, Pamela L Boner, Dave D W Liu, 2003, Journal of agricultural and food chemistry.

Flunixin residues in milk after intravenous treatment of dairy cattle with (14)C-flunixin.

J. W. Campbell, W. Feely, K. Thompson, 2002, Journal of agricultural and food chemistry.

Determination of flunixin in edible bovine tissues using liquid chromatography coupled with tandem mass spectrometry.

W. Feely, R. Robinson, Pamela L Boner, 2003, Journal of agricultural and food chemistry.

Immobility of Emamectin Benzoate in Soils

W. Feely, P. Wislocki, M. Mushtaq, 1996 .

Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis.

J. Prieto, B. Sangro, T. Crocenzi, 2013 .

Dermal penetration of 4"-(epi-methylamino)-4"-deoxyavermectin B1a benzoate in the rhesus monkey.

W. Feely, W. Feeney, L. Crouch, 1997, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.

C. Horak, J. Wolchok, M. Sznol, 2013 .

Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).

C. Horak, J. Wolchok, M. Sznol, 2013 .

Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.

W. Feely, R. Preston, Samir K. Gupta, 2012, Clinical pharmacokinetics.

Uptake of emamectin benzoate residues from soil by rotational crops

W. Feely, T. Burnett, A. Chukwudebe, 1996 .

P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073

M. Kudo, B. Sangro, J. Neely, 2021, Annals of Oncology.